These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24930623)

  • 1. Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.
    Robinson AG; Booth CM; Eisenhauer EA
    Eur J Cancer; 2014 Sep; 50(13):2298-302. PubMed ID: 24930623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
    Robinson AG; Booth CM; Eisenhauer EA
    Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill S; Sargent D
    Oncologist; 2006 Jun; 11(6):624-9. PubMed ID: 16794241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.
    Driscoll JJ; Rixe O
    Cancer J; 2009; 15(5):401-5. PubMed ID: 19826360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General and statistical hierarchy of appropriate biologic endpoints.
    Sargent D
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?
    Saad ED; Buyse M
    J Clin Oncol; 2012 May; 30(15):1750-4. PubMed ID: 22393092
    [No Abstract]   [Full Text] [Related]  

  • 9. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
    Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
    Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 11. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 13. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
    Zhuang SH; Xiu L; Elsayed YA
    Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable disease is a valid end point in clinical trials.
    Tolcher AW
    Cancer J; 2009; 15(5):374-8. PubMed ID: 19826356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endpoints for assessing drug activity in clinical trials.
    Pazdur R
    Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
    Mailankody S; Prasad V
    JAMA Oncol; 2017 Jul; 3(7):889-890. PubMed ID: 27892992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.